title: Inhibitory effects of (1R,9S)-beta-Hydrastine on calcium transport in PC12 cells.
abstract: (1R,9S)-beta-Hydrastine (BHS), at 100 microM, has been shown to mainly reduce the K+-induced dopamine release and Ca2+ influx by blocking the L-type Ca2+ channel and inhibit the caffeine activated store-operated Ca2+ channels, but not those activated by thapsigargin, in PC12 cells. In this study, the effects of BHS on Ca2+ transport from Ca2+ stores in the absence of external Ca2+ were investigated in PC12 cells. BHS decreased the basal intracellular Ca2+ concentration ([Ca2+]i) in the absence of external Ca2+ in PC12 cells. In the absence of external Ca2+, pretreating PC12 cells with 100 microM BHS reduced the rapid increase in the [Ca2+]i elicited by 20 mM caffeine, but not that by 1 microM thapsigargin. In addition, BHS inhibited the increase in the [Ca2+]i elicited by restoration of 2 mM CaCl2 after the Ca2+ stores had been depleted by 20 mM caffeine, but not those depleted by 1 microM thapsigargin, in the absence of external Ca2+. These results suggested that BHS mainly inhibited Ca2+ leakage from the Ca2+ stores and the caffeine-stimulated release of Ca2+ from the caffeine-sensitive Ca2+ stores in PC12 cells.
authors.affiliation: College of Pharmacy, and Research Center for Bioresource and Health, Chungbuk National University, Cheongju 361-763, Korea.
authors.forename: Shou Yu
authors.initials: SY
authors.lastname: Yin
authors.forename: Chun Mei
authors.initials: CM
authors.lastname: Jin
authors.forename: Yoo Jung
authors.initials: YJ
authors.lastname: Yang
authors.forename: Sung Cil
authors.initials: SC
authors.lastname: Lim
authors.forename: Chong Kil
authors.initials: CK
authors.lastname: Lee
authors.forename: Bang Yeon
authors.initials: BY
authors.lastname: Hwang
authors.forename: Jai Seup
authors.initials: JS
authors.lastname: Ro
authors.forename: Myung Koo
authors.initials: MK
authors.lastname: Lee
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D044182:Benzylisoquinolines / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016716:PC12 Cells; D051381:Rats; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013237:Stereoisomerism; D019284:Thapsigargin / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000470:Alkaloids; D044182:Benzylisoquinolines; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D019284:Thapsigargin; C013024:hydrastine; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D002118:Calcium